MedTrace Logo

Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors

NCT00569738 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2009-02-17

No results posted yet for this study

Summary

Imaging of neuroendocrine tumors (NETs) relies on conventional morphological methods and on somatostatin receptor scintigraphy (SRS). SRS is effective for carcinoid tumors, and for most pancreatic islet-cell tumors, but may fail to detect some tumors. Furthermore, this technique may require repeated imaging over 24-48 hours. Introduction of newer somatostatin analogs such as DOTANOC improves lesion detection. In addition, labeling with Ga68 and use of PET/CT improves the pharmacokinetics of the tracer resulting in better tumor visualization, and an easier procedure with imaging over only 1-2 hours.

In this study, we propose to use Ga68-DOTANOC PET for imaging of various NETs, comparing the imaging data to those of anatomical and other functional modalities, and to histopathology, when available.

Conditions

  • Neuroendocrine Tumor

Interventions

PROCEDURE

PET scan with Ga68-DOTANOC

Imaging: PET scan with Ga68-DOTANOC

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Yodphat Krausz, MD · Hadassah Medical Organization

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Completion
2010-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00569738 on ClinicalTrials.gov